At a glance
Journal article in Dialysis & Transplantation, 2006. Written by Michele B. Kaufman. 7 references.
Abstract (original language)
Three new insulin products were recently FDA approved: Apidra (insulin glulisine, Aventis), Exubera (inhaled human insulin, Pfizer/Nektar), and Levemir (insulin detemir, NovoNordisk). It is important to know some basic information about these agents because your patients may be receiving them, and may come to you with questions about their use. Apidra (insulin glulisine) is rapid acting, with peak concentrations occurring within approximately 1 hour. Apidra should be taken 15 minutes before a meal or 20 minutes after starting a meal. As with other insulin analogs, it should not be mixed with other insulins.1 The Apidra dose should be reduced in patients with renal dysfunction, as higher circulating levels of the drug were seen in study subjects with moderate to severe renal impairment. Therefore, it is recommended that glucose and insulin dose adjustments in these renal patients be carefully monitored. Insulin lispro and insulin aspart have the same renal recommendations.2,3 Levemir (insulin detemir, NovoNordisk) is a basal insulin similar to Lantus (glargine, Sanofi-Aventis) that is recommended for once or twice daily subcutaneous dosing as part of a basal-bolus regimen for adults and children with diabetes. It has a slow, flat absorption with a long duration of action, ranging from 5.7 to 23.2 hours. Its maximum serum concentrations occur within 6–8 hours of dosing.4 The Apidra dose should be reduced in patients with renal dysfunction. As with other insulin products, patients with renal dysfunction may have higher levels of circulating insulin; therefore, it is recommended that the glucose of these patients be carefully monitored and the insulin dose adjusted accordingly. Exubera (inhalation powder, human insulin) is the result of collaboration between Nektar Therapeutics and Pfizer/Aventis Pharmaceuticals.7 It was FDA approved in January and is expected to be available this summer. It is a short-acting insulin product approved for use in adults with type 1 or 2 diabetes mellitus. It can also be used with oral agents or with a basal insulin for basal/bolus dosing. Common side effects reported in clinical trials were cough, sore throat, shortness of breath, dry mouth, and hypoglycemia. Exubera is not recommended for current smokers, patients who have recently quit smoking, asthmatics, or those with bronchitis or emphysema. Because inhaled insulin is a new model for diabetes drug delivery, its long-term safety is unknown. Monitoring parameters specific for Exubera include baseline pulmonary function tests (PFTs) and follow-up PFTs every 6–12 months until more is known about the drug's pulmonary safety. There are no known renal recommendations at this time. Only time will tell whether Exubera will become a blockbuster agent, and whether it will improve diabetic control in poorly controlled/difficult to manage patients. The delivery of insulin ‘not by injection’ may be the only advantage of this new product.
Cite
APA
Kaufman, M. B. (2006). The new insulins. Dialysis & Transplantation. https://doi.org/10.1002/dat.20025
Vancouver
Kaufman MB. The new insulins. Dialysis & Transplantation. 2006. doi:10.1002/dat.20025
BibTeX
@article{Kaufman2006,
author = {Kaufman, Michele B.},
title = {The new insulins},
journal = {Dialysis & Transplantation},
year = {2006},
doi = {10.1002/dat.20025}
}
EUVIMED